Research programme: anti-infectives - GlycoMimetics

Drug Profile

Research programme: anti-infectives - GlycoMimetics

Alternative Names: Carbohydrate mimics for bacterial infections - GlycoMimetics; GMI-1051

Latest Information Update: 02 Nov 2014

Price : $50

At a glance

  • Originator GlycoMimetics
  • Class Small molecules
  • Mechanism of Action Lectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pseudomonal infections

Most Recent Events

  • 08 Sep 2014 Pharmacodynamics data from preclinical studies in pseudomonal infections released by GlycoMimetics
  • 03 Aug 2006 GMI 1051 has been selected as lead candidate for the treatment of Pseudomonal infections
  • 20 Nov 2004 Preclinical trials in Pseudomonal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top